In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Institut Pasteur

Executive Summary

The 125-year old Institut Pasteur has never relied entirely on state funding: today, only a third of its €174 million ($170 million) budget comes from the health and research ministries. In part due to changes instituted in the last two years, license fees and the exploitation of the Pasteur trademark now provide about 45% of Pasteur's budget-with €72 million generated in 2001. And the efforts of the Institute to do technology transfer have resulted in the creation of nine start-ups in the past four years.

You may also be interested in...



Hybrigenics SA

The Institut Pasteur, France's leading private medical research institution, has licensed some of its functional proteomics technology to Hybrigenics SA and houses the start-up on its campus, providing it with various technology support functions. Hybrigenics is using automated functional proteomics systems for research into infectious diseases and cancer.

CTG Pharma SRL

CTG Pharma SRL's founders believe that the unique properties of hydrogen sulfide (H2S) hold the key to exciting new anti-inflammatory therapeutics. The Italian start-up plans to tag already-approved compounds with an H2S-releasing molecule. The strategy has several potential advantages: it would create novel chemical entities, it would reduce the risks of drug development, and it could be applied with a variety of drugs.

GeneMedix's Big Biogeneric Gamble

Patent expiries in Europe on proteins such as EPO and interferon alpha may open up a huge market for cheaper versions of these proteins-one which GeneMedix and others are preparing to tap into. But it's a risky game, since there's still no regulatory process in Europe for approving such products.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel